返回
HBM Holdings Limited（2142.HK）價格
2142.HK 股價走勢圖
HBM HOLDINGS-B (2142.HK)
HBM Holdings Limited
HK$14.38
-1.03%
$-0.14
休市： Jan 16, 16:00:00 HKT
Earnings FAQ
2142.HK 最近的每股盈餘與預期相比如何？
HBM Holdings Limited 2142.HK 上一季度的收入表現如何？
HBM Holdings Limited 的收入預期是多少？
HBM Holdings Limited 的盈利品質評分是多少？
HBM Holdings Limited 何時發布財報？
HBM Holdings Limited 的預期收益是多少？
HBM Holdings Limited 是否超出收益預期？
關鍵數據
前收市價
$14.53
開盤價
$14.53
當日範圍
$14.08 - $14.68
52週區間
$2.9 - $17.98
交易量
2.8M
平均成交量
4.4M
每股盈餘 (TTM)
0.73
股息收益率
--
市值
$12.0B
什麼是 HBM HOLDINGS-B？
HBM Holdings Ltd. is an investment company, which engages in the discovery and development of differentiated antibody therapeutics in oncology and immunology disease areas. The company is headquartered in Suzhou, Jiangsu and currently employs 210 full-time employees. The company went IPO on 2020-12-10. The Company’s products primarily include BATOCLIMAB (HBM9161), HBM9378, HBM7020, TCE Program, PORUSTOBART (HBM4003), HBM7022 and others. The products are primarily used to treat generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal carcinoma (CRC) and solid tumors. The firm provides next-generation antibody and biotherapeutic solutions through proprietary antibody technology platforms including Harbour Mice, HBICE, HBICA and single B cell cloning platform.